BACKGROUND: International guidelines recommend at least three months anticoagulation in all patients after acute venous thromboembolism (VTE) and suggest those with unprovoked events be considered for indefinite anticoagulation if the risk of recurrence is high and the risk of bleeding during treatment non-high. Other authors have recently argued against using a dichotomy unprovoked/provoked events to decide on anticoagulation duration and suggest instead using overall risk factors present in each patient as the basis for deciding. AIM: This sub-analysis of the WHITE study aimed at assessing the reasons for the treatment decisions taken by doctors in different countries. RESULTS: 1240 patients were recruited in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia). Anticoagulation was extended in 51.7% and 49.3% of patients with unprovoked or provoked events (n.s.); stopped in 15.4% versus 28.9% (P < .0001), and changed to antithrombotic drugs (sulodexide or aspirin) in 32.9% versus 21.8% (P < .0001). In the 430 subjects with isolated distal deep vein thrombosis (IDDVT) anticoagulation was stopped in 34.4%, continued in 37.0% (mainly those with post-thrombotic syndrome [PTS]) and switched to antithrombotics in the balance. High risk of recurrence was the most prevalent reason (>83% of cases) given to continue anticoagulation, regardless of nature and site of the index events, followed by risk of bleeding and presence of PTS signs. CONCLUSION: On average, attending physicians estimated the risk of recurrence in real life conditions, and the consequent therapeutic decision, using all the information available, not limiting to the location or nature of the index event.

Angiology Unit 9308University of Padua Padova Italy

Arianna Anticoagulazione Foundation Bologna Italy

Clinic of Angiology Comenius University and National Institute of Cardiovascular Diseases Bratislava Slovakia

Clinical Hospital N 1 Volynskaya Moscow Russia

Clinical Trial Centre Hodonin Czechia

Faculty of Medicine of Tunis 59074University of Tunis El Manar Tunis Tunisia

Medical University of Silesia Katowice Poland

North West Mechnikov State Medical University St Petersburg Russia

Peking Union Medical College 12501Chinese Academy of Medical Sciences Beijing China

School of Specialization in Hospital Pharmacy 9304University of Milan Milan Italy

University of Porto Porto Portugal

Zobrazit více v PubMed

Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1, 626 patients. Haematol Hematol J. 2007;92(2):199-205. PubMed

Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. DOI: 10.1016/j.chest.2015.11.026 PubMed DOI

Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018;39(47):4208-4218. DOI: 10.1093/eurheartj/ehx003. PubMed DOI

Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J. 2020;41(4):543-603. DOI: 10.1093/eurheartj/ehz405. PubMed DOI

G NICE. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158). NICE Guid. 2020. https://www.nice.org.uk/guidance/ng158

Kakkos SK, Gohel M, Baekgaard N, et al. Editor’s choice - European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9-82. DOI: 10.1016/j.ejvs.2020.09.023. PubMed DOI

Riva N, Bellesini M, Di Minno MN, et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost. 2014;112(3):511-521. DOI: 10.1160/TH14-01-0081 PubMed DOI

Palareti G, Antonucci E, Ageno W, et al. The American college of chest physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply. J Thromb Haemost. 2018;16(12):2539-2540. DOI: 10.1111/jth.14300. PubMed DOI

Wallace R, Anderson MA, See K, et al. Venous thromboembolism management practices and knowledge of guidelines: a survey of Australian haematologists and respiratory physicians. Intern Med J. 2017;47(4):436-446. DOI: 10.1111/imj.13382. PubMed DOI

de Winter MA, Remme GCP, Kaasjager K, et al. Short-term versus extended anticoagulant treatment for unprovoked venous thromboembolism: a survey on guideline adherence and physicians’ considerations. Thromb Res. 2019;183:49-55. DOI: 10.1016/j.thromres.2019.10.003. PubMed DOI

Antonucci E, Migliaccio L, Abbattista M, et al. Treatment decision-making of secondary prevention after venous thromboembolism: data from the real-life START2-POST-VTE register. Clin Appl Thromb Hemost. 2020;26. DOI: 10.1177/1076029620945792. PubMed DOI PMC

Palareti G, Bignamini AA, Cini M, et al. Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries: the prospective, international, observational WHITE study. Intern Emerg Med. 2021. DOI 10.1007/s11739-021-02765-1 PubMed PMC

Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710-1716. DOI: 170/19/1710 [pii] 10.1001/archinternmed.2010.367. PubMed

Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103(20):2453-2460. PubMed

Galanaud JP, Quenet S, Rivron-Guillot K, et al. Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis versus proximal deep vein thrombosis in 11 086 patients. J Thromb Haemost. 2009;7(12):2028-2034. DOI: JTH3629 [pii] 10.1111/j.1538-7836.2009.03629.x. PubMed

Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-1636. DOI: CIRCULATIONAHA.109.925214 [pii] 10.1161/CIRCULATIONAHA.109.925214. PubMed

Ageno W, Mantovani LG, Haas S, et al. Patient management strategies and long-term outcomes in isolated distal deep-vein thrombosis versus proximal deep-vein thrombosis: findings from XALIA. TH Open. 2019;3(1):e85-e93. DOI: 10.1055/s-0039-1683968. PubMed DOI PMC

Schellong SM, Goldhaber SZ, Weitz JI, et al. Isolated distal deep vein thrombosis: perspectives from the GARFIELD-VTE registry. Thromb Haemost. 2019;119(10):1675-1685. DOI: 10.1055/s-0039-1693461. 2019/08/02. PubMed DOI

Palareti G, Legnani C, Antonucci E, et al. Management and outcomes of isolated distal deep vein thrombosis: a questionable trend toward long-lasting anticoagulation treatment. Results from the START-Register. TH Open. 2021;5(3):e239-e250. DOI 10.1055/s-0041-1730038 PubMed PMC

Palareti G, Antonucci E, Legnani C, et al. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. BMJ Open. 2020;10(11):e040449. DOI: 10.1136/bmjopen-2020-040449. PubMed DOI PMC

Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13):1062-1071. DOI: CIRCULATIONAHA.114.008828 [pii]10.1161/CIRCULATIONAHA.114.008828 [doi]. PubMed

Andreozzi GM, Bignamini AA, Davi G, et al. Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 2015;132(20):1891-1897. DOI: 10.1161/CIRCULATIONAHA.115.016930 PubMed DOI PMC

Pompilio G, Integlia D, Raffetto J, et al. Comparative efficacy and safety of sulodexide and other extended anticoagulation treatments for prevention of recurrent venous thromboembolism: a Bayesian network meta-analysis. TH Open. 2020;4(2):e80-e93. DOI: 10.1055/s-0040-1709731. PubMed DOI PMC